logo

For the Inventor, By the Inventor

Stanford, CA, United States of America

Bingwei Lu

This inventor holds 9 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignees: Leland Stanford Junior University, Cerepeut, Inc.. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bingwei Lu. Retrieved from https://idiyas.com/inventor/bingwei-lu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 55.6

 

Average Co-Inventor Count = 1.4

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Palo Alto, CA (US) (2018)
  • Stanford, CA (US) (2016 - 2024)

Company Filing History:

goldMedal5 out of 5,515 
 
Leland Stanford Junior University
 patents
silverMedal4 out of 4 
 
Cerepeut, Inc.
 patents

Years Active: 2016-2025

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 12454514 - Quinazolinone compounds (2025-10-28),
2. 12404251 - Small molecule compound (2025-09-02),
3. 11912669 - Small molecule compound (2024-02-27),
4. 11186550 - Small molecule compound (2021-11-30),
5. 10149860 - Compositions and methods for treating alzheimer's disease and other tauopathies (2018-12-11),
6. 9730935 - Targeting a non-canonical notch signaling pathway for cancer treatment (2017-08-15),
7. 9719090 - Methods of trans-differentiating a terminally differentiated target cell to a neuron (2017-08-01),
8. 9289448 - Compositions and methods for treating alzheimer's disease and other tauopathies (2016-03-22),
9. 9265788 - Compositions and methods for treatment of mitochondrial diseases (2016-02-23),

Title: Bingwei Lu: Innovator in Mitochondrial Dysfunction Treatments

Introduction

Bingwei Lu is a prominent inventor based in Stanford, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of treatments for diseases associated with mitochondrial dysfunction. With a total of 9 patents, his work has the potential to impact various medical conditions.

Latest Patents

Among his latest patents, Lu has developed new quinazolinone compounds. These compounds are disclosed along with pharmaceutical compositions that contain quinazolinones and methods for treating diseases related to mitochondrial dysfunction. Another notable invention is a small molecule compound that relates to compositions and methods for treating cancer and other diseases associated with mitochondrial dysfunction. This includes neurodegenerative diseases, brain injuries, and certain non-neurological disorders, utilizing a novel compound known as 6-chloro-3-(2,4-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4(3H)-one and its derivatives.

Career Highlights

Bingwei Lu has worked with esteemed institutions such as Leland Stanford Junior University and Cerepeut, Inc. His research and innovations have garnered attention in the scientific community, contributing to advancements in medical treatments.

Collaborations

Lu has collaborated with notable coworkers, including Seongsoo Lee and Kyu-Sun Lee. Their joint efforts have furthered research in the field of mitochondrial dysfunction and its related diseases.

Conclusion

Bingwei Lu's innovative work in developing treatments for mitochondrial dysfunction showcases his dedication to advancing medical science. His contributions through patents and collaborations highlight the importance of research in improving health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…